INDIANAPOLIS – The Indiana University School of Medicine is promoting one of its own to serve as the next leader of the Department of Urology.
Clint Cary, MD, MPH, MBA, has been named the new chair, succeeding Michael Koch, MD, who served in the role for 26 years. The department is currently ranked No. 24 in National Institutes of Health funding among urology departments in the United States.
A highly respected clinician-scientist in the field of urologic oncology, Cary is currently an associate professor of urology at the IU School of Medicine. With a particular interest in the surgical management of advanced testicular cancer and bladder cancer, Cary's research efforts focus on health services and outcomes research in testis and bladder cancer.
"Dr. Cary's extensive clinical and research experience have uniquely prepared him to lead and transform our Department of Urology," said Jay L. Hess, MD, PhD, MHSA, dean of IU School of Medicine and executive vice president of university clinical affairs for IU. "Throughout his career at the school, Dr. Cary has shown a commitment to research and improving clinical care for patients. I am eager for him to continue that leadership as our new chair for urology."
Cary has spent 18 years with the Department of Urology at the IU School of Medicine, beginning his urology training there as a resident. Since then, he has held several leadership roles within the department, as well as with state and national associations. He served as the director of genitourinary oncology research for five years, during which time he helped organize the oncology research within the group. In his role as director of the Urologic Germ Cell Tumor Program at IU, he published numerous clinical studies in high-impact oncology journals — the findings of which have been incorporated in guidelines on testicular cancer management issued by the American Urological Association and the National Comprehensive Cancer Network.
Leading or participating in 106 peer-reviewed publications and book chapters across urologic oncology topics, Cary has been widely recognized for his research efforts. He served as the site principal investigator on a multi-institutional Phase II trial across 12 sites in the U.S. and Canada exploring the treatment option of RPLND for patients with clinical state II seminoma. Under Cary’s leadership, IU was the highest enrolling site. This study led to the new treatment option of surgery for these patients. Cary's research has received grant funding from the NIH to study patterns of care and decisions around intravesical chemotherapy use at the time of surgery for non-muscle invasive bladder cancer. This work has led to a better understanding of how well-designed interventions can potentially reduce cancer recurrences for patients.
In addition to his leadership at the IU School of Medicine, Cary also shares his expertise with colleagues at the state and national level. He previously served as the treasurer/secretary of the Indiana Urologic Association, for which he currently serves as the president-elect. Nationally, he serves as the section editor for the Testicular Cancer Core Curriculum of the American Urological Association. In this role, he leads a team of urologists and medical oncologists from around the U.S. to annually provide the most up-to-date literature serving as a large educational resource for residents, fellows and practicing urologists.
"My time with the department here at IU has provided me the environment to succeed and become the academic urologist I envisioned," Cary said. "I am tremendously grateful for this opportunity and am eager to help lead others toward their professional goals in this new role."
Cary graduated summa cum laude from the University of Tennessee in 2001 with a bachelor’s degree in biochemistry, cellular and molecular biology. He received his MD from the University of Tennessee Health Science Center in 2005, and completed his urology residency at IU School of Medicine in 2011. He went on to complete a two-year urologic oncology fellowship at the University of California, San Francisco. In addition to his fellowship, he received a Master of Public Health with a concentration in epidemiology from the University of California, Berkeley. Most recently, he completed his MBA with the IU Kelley School of Business.
He will assume the role effective Oct. 1 and will have oversight and responsibility for the program's clinical, educational and research programs.
About the IU School of Medicine
The IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability. According to the Blue Ridge Institute for Medical Research, the IU School of Medicine ranks No. 13 in 2023 National Institutes of Health funding among all public medical schools in the country.
Writer: Katie Duffey, kaduffey@iu.edu
For more news, visit the IU School of Medicine Newsroom: medicine.iu.edu/news
Follow us on X: @IUMedSchool